Title
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy
Authoring Organization
Publication Month/Year
November 1, 2021
Last Updated Month/Year
February 6, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Target Patient Population
Adult patients with cancer receiving treatment with immune checkpoint blockade inhibitors alone.
Target Provider Population
Oncologists, medical specialists, emergency medicine, family practitioners, nurses, and pharmacists
Inclusion Criteria
Male, Female, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Emergency care, Hospital, Outpatient
Intended Users
Healthcare business administration, nurse, nurse practitioner, community pharmacist, health systems pharmacist, physician, physician assistant
Scope
Management, Prevention
Diseases/Conditions (MeSH)
D007167 - Immunotherapy, D064420 - Drug-Related Side Effects and Adverse Reactions, D000082082 - Immune Checkpoint Inhibitors
Keywords
immune checkpoint inhibitor (ICI), Immune Checkpoint Inhibitor, Immune-Related Adverse Events, IRAEs, Cancer immunotherapy, Keytruda, Opdivo, ICPis
Source Citation
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36): 4073-4126. doi: 10.1200/JCO.21.0.1440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. PM ID: 34724392